Trevi Therapeutics Announces Third Quarter 2021 Financial Results and Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Trevi Therapeutics (TRVI) PT Lowered to $8 at Needham & Company
November 11, 2021 6:47 AM ESTNeedham & Company analyst Serge Belanger lowered the price target on Trevi Therapeutics (NASDAQ: TRVI) to $8.00 (from $10.00) while maintaining a Buy rating.
The analyst commented, "TRVI reported 3Q21 financials and provided a corporate update. The ph 2b/3 PRISM trial, evaluating Haduvio (nalbuphine ER) as... More
Trevi Therapeutics (TRVI) Tops Q3 EPS by 6c
November 10, 2021 4:27 PM ESTTrevi Therapeutics (NASDAQ: TRVI) reported Q3 EPS of ($0.34), $0.06 better than the analyst estimate of ($0.40).
For earnings history and earnings-related data on Trevi Therapeutics (TRVI) click here.
... More